Pheochromocytoma is a type of benign tumour that occurs in medulla of the adrenal glands which leads to excess release of adrenaline. The tumour forms in the nerve tissue of the adrenal glands. There are two adrenal glands present on the top of each kidney. Each adrenal gland comprises of adrenal cortex and adrenal medulla. Catecholamines such as adrenaline and noradrenaline, controls blood pressure, heart rate, and blood sugar. Pheochromocytoma can be diagnosed by blood-catecholamine test, urine test computed tomography, and magnetic resonance imaging. National Cancer Institute, France is in the process of developing sunitinib as an angiogenesis inhibitor for the treatment of pheochromocytoma. Tarveda Therapeutics, Inc. is in the process of developing PEN-221 as a somatostatin receptor 2 modulator for the treatment of pheochromocytoma. Some of the companies and universities having the pipeline of pheochromocytoma include Tarveda Therapeutics, Inc., University of California, Los Angeles, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.